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Synopsis 86	  
Background: Atazanavir without ritonavir, despite efficacy and tolerability, shows low plasma 87	  
concentrations that warrant optimization. 88	  
Methods: In a randomized, controlled, pilot trial, stable HIV-positive patients on 89	  
atazanavir/ritonavir (with tenofovir/emtricitabine) were switched to atazanavir. In the standard dose 90	  
arm atazanavir was administered as 400 mg once-daily, while according to patients’ genetics (PXR, 91	  
ABCB1 and SLCO1B1) in the pharmacogenetic arm: patients with unfavourable genotypes received 92	  
atazanavir 200 mg twice-daily.  93	  
Results: Eighty patients were enrolled with balanced baseline characteristics. Average atazanavir 94	  
exposure was 253 ng/mL (150-542) in the pharmacogenetic arm versus 111 ng/mL (64-190) in the 95	  
standard arm (p<0.001); 28 patients in the pharmacogenetic arm (75.7%) had atazanavir exposure 96	  
>150 ng/mL versus 14 patients (38.9%) in the standard arm (p=0.001). Immunovirological and 97	  
laboratory parameters had a favourable outcome throughout the study with non-significant 98	  
differences between study arms. 99	  
Conclusions: Atazanavir plasma exposure is higher when the schedule is chosen according to the 100	  
patient’s genetic profile. 101	  
 102	  
 103	  
 104	  
 105	  
 106	  
 107	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INTRODUCTION 108	  
In the lifelong perspective of anti-HIV treatment, individual tailoring of the antiretroviral regimen is 109	  
going to be increasingly required. Although never formally approved in Europe, the use of 110	  
atazanavir without concurrent intake of ritonavir has been shown to be effective and well tolerated 111	  
in two induction-maintenance clinical trials of relevant size and several retrospective studies. 1-4 112	  
However in a significant proportion of patients the pharmacokinetic (PK) exposure of atazanavir 113	  
might be potentially insufficient to guarantee long-term HIV inhibition.5,6 atazanavir lower 114	  
exposure when combined with tenofovir disoproxil fumarate has been shown in healthy volunteers 115	  
but subsequently found to be less relevant in HIV-positive patients.7-9 atazanavir  pharmacokinetics 116	  
is significantly influenced by genetic polymorphisms in the region coding for the pregnane X 117	  
receptor (PXR, controlling the expression of several genes involved in drug metabolism and 118	  
transport); additionally polymorphisms in ABCB1 (coding for P-glycoprotein) and SLCO1B1 119	  
(coding for OATP1B1) were shown to have a comparable effect on atazanavir exposure.10-12 120	  
Furthermore we observed that the pharmacokinetic exposure of atazanavir was significantly 121	  
improved when administered 200 mg twice-daily instead of 400 mg once-daily.13  122	  
We report here the results of a randomized comparative study on the clinical use of unboosted 123	  
atazanavir with or without pharmacogenetic guide in patients also taking co-formulated 124	  
tenofovir/emtricitabine. 125	  
 126	  
METHODS 127	  
HIV-positive adult patients on treatment with atazanavir/ritonavir (300/100 mg) plus 128	  
tenofovir/emtricitabine with HIV RNA <50 copies/mL for at least six months were eligible for 129	  
enrolment at two sites in Italy. Switch to atazanavir was proposed for toxicity/tolerability or for 130	  
simplification, according to physicians’ evaluation in clinical practice. Exclusion criteria were: 131	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previous virological failure, genotypic resistance-associated mutations, ongoing opportunistic 132	  
infections/neoplasias, liver cirrhosis, chronic renal failure, self-reported adherence <90% (Visual 133	  
Scale) and consumption of potentially interacting drugs. 134	  
The study was approved by the institutional review board at both participating centres, and each 135	  
participant provided signed informed consent before enrolment; the procedures were in accordance 136	  
with the ethical standards of the Helsinki Declaration of 1975 (as revised in 1983). 137	  
The study was a randomized, controlled, open-label, pilot trial.  Patients were randomized 1:1 138	  
(block randomization) to either standard-dose arm [“SD”; atazanavir 400 mg once daily] or 139	  
pharmacogenetic-based arm [“PG”; atazanavir 400 mg once daily in patients with favourable 140	  
genetic profile or atazanavir 200 mg twice daily in patients with unfavourable genetic profile].At 141	  
enrolment genomic DNA was extracted using QIAamp whole blood mini kit (Qiagen, Valencia, 142	  
CA, USA) and genotyping was conducted by real time-based allelic discrimination with the use of 143	  
standard methods (BIORAD, Milano, Italy). The following single nucleotide polymorphisms were 144	  
analysed: C63396T in PXR (rs2472677), C3435T in ABCB1 (rs1045642) and C521T in SLCO1B1 145	  
(rs4149056).  PXR 63396 TT, ABCB1 3435 CT/TT and SLCO1B1 521 TT were codified as 1 146	  
(associated with lower plasma concentrations). On the basis of the PG results patients were given a 147	  
score (min zero - max three) and a different dosing schedule according to favourable (≤1) or 148	  
unfavourable genetic profiles (≥2).  149	  
Primary end point was the prevalence of atazanavir average trough concentrations (geometric mean 150	  
of the first three determinations at weeks 4, 8 and 12) above 150 ng/mL (suggested target plasma 151	  
level) in the two arms. Secondary end points were the comparison of the proportion of patients with 152	  
HIV RNA <50 copies/mL and of the changes in indirect bilirubin, total cholesterol, LDL-153	  
cholesterol, HDL-cholesterol and triglycerides at 48 weeks.  154	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atazanavir trough plasma concentrations [12/24 hours after drug intake according to drug schedule 155	  
(± two hours)] were measured by a previously validated HPLC-PDA (Photo Diode Array) method 156	  
and performed in Torino.14 157	  
A sample size of 80 patients (40 per group) was calculated to provide a statistical power of at least 158	  
80%, in order to identify a difference in mean atazanavir Ctrough below the MEC of 150 ng/mL 159	  
between the two study arms. It was assumed a 20% of atazanavir Ctrough under MEC in the PG 160	  
arm, and a 50% in the control arm from previous studies results.10-12 Standard non-parametric tests 161	  
were usd for all analysis and performed using SPSS 20.0 software for Mac (SPSS, IBM Inc.). 162	  
 163	  
RESULTS 164	  
Eighty patients were enrolled (2009-2011): demographic and immunovirological characteristics 165	  
were well balanced between study arms (Table 1). Patients’ disposition is shown in Figure S1: no 166	  
subject dropped out of the study due to toxicity, virological failure or major clinical events. The 167	  
prevalence of single nucleotide polymorphisms is reported in Table 1; all variants were in Hardy-168	  
Weinberg equilibrium. 27 patients in the PG arm received atazanavir 200 mg twice daily. 169	  
Atazanavir plasma trough concentrations are shown in Figure S2 and Table S1. Atazanavir Ctrough 170	  
was slightly higher at baseline in the PG arm [1034 ng/mL (592-1935) versus. 587 ng/mL (77-171	  
1290), Mann-Whitney p=0.06] as compared to SD arm; it was significantly higher at every time 172	  
point after randomization (p<0.001 for all comparisons, Mann-Whitney) in the PG arm.  173	  
Geometric mean of week 4 to 12 atazanavir Ctroughs was 253 ng/mL (150-542) in the PG arm 174	  
versus 111 ng/mL (64-190) in the SD arm, favouring the former (p<0.001, Mann-Whitney). As for 175	  
the primary endpoint 28 patients in the PG arm (75.7%) had an average atazanavir Ctrough above 176	  
150 ng/mL versus 14 patients (38.9%) in the SD arm (p=0.001, RR 4.89, 95%CI 1.79-13.38) (Fig. 177	  
1). 178	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No difference in plasma HIV-RNA <50 copies/mL was observed in 37 patients (100%) in the PG 179	  
arm versus 33 patients (97%) in the SD arm at week 48. Three patients (8.1%) and 4 patients 180	  
(11.7%) in the PG and SD arm presented a viral blip during the study (p=0.703, Fisher’s exact test). 181	  
Patients in both arms had similar CD4+ T lymphocytes recovery at week 48: 39 cells/mm3 in the 182	  
PG versus 53 cells/mm3 in the SD arm (p=0.744, Mann-Whitney). 183	  
At 48 weeks significant decreases (all p<0.05, Wilcoxon’s) in safety markers were noted as 184	  
compared to baseline: no significant differences between study arms were found (Mann-Whitney), 185	  
(Table S2). 186	  
 187	  
DISCUSSION 188	  
In this pilot, randomized and controlled study we found that the pharmacokinetic exposure of 189	  
atazanavir, when co-administered with tenofovir/emtricitabine was significantly higher and closer 190	  
to the desired target concentration when the frequency of administration was chosen according to 191	  
the patient’s genetic profile. The proportion of patients with atazanavir Ctrough above the cut-off 192	  
concentration rose from 40% (previous studies and the standard arm) to 75.7% (study arm) when 193	  
the frequency of atazanavir administration (400 mg once daily or 200 mg twice daily) was decided 194	  
on the basis of the individual genotypic profile.10-12 Although not all patients had a Ctrough level 195	  
above the pre-specified cut-off value of 150 ng/mL, the pharmacokinetic exposure in the study arm 196	  
was found significantly more appropriate than in patients in the control arm.  In the PG arm baseline 197	  
atazanavir levels were higher than those recorded in the SD arm: it is possibly due to unbalanced 198	  
factors between study arms (such as CYP3A5 genotype and adherence levels) and unexpected 199	  
atazanavir exposures according to genotype (Supp.Tab.1) may support this hypothesis.15 It must 200	  
however be considered that the 150 ng/mL threshold resulted from the analysis of a moderately 201	  
experienced population of HIV-infected patients that was no longer formally re-assessed in 202	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treatment-naïve patients: it appears possible that it could be lower in patients not harbouring virus 203	  
with resistance associated mutations and after achieving viral suppression.6,16,17 The documented 204	  
higher intracellular accumulation of atazanavir as compared to other PIs might also support this 205	  
hypothesis. 18,19 No significant difference in the prevalence of viral control or in the changes in 206	  
safety markers between study arms was seen: it is possible the longer follow-up may be required to 207	  
observe the effect of improved pharmacokinetic exposure or that lower atazanavir concentrations 208	  
may be adequate. 209	  
Independently of study arm atazanavir-based regimens were well tolerated and associated with 210	  
improved safety profiles. Even if the drug is nowadays less used given the availability of safe and 211	  
very compact antiretroviral regimens it may be very useful in the long-term treatment of HIV-212	  
positive patients. The absence of ritonavir (associated with side effect even at low doses) and the 213	  
uncommon incidence of hyperbilirubinmia (being the main determinant of atazanavir/ritonavir 214	  
inferior performance in naïve patients) support the attractiveness of atazanavir-containing 215	  
regimens.20 Even if the need for genetic testing prior to start atazanavir might no be commonly 216	  
accepted it can be a tool for avoiding unnecessary treatment interruptions and side effects.21 217	  
Although some patients (those with unfavourable genetic profile) would necessitate to take the drug 218	  
twice daily instead of once daily, the advantage in terms of side effects reduction might compensate 219	  
the higher frequency of administration. 220	  
We have to recognize some limitations of this study: the limited sample size, the restricted number 221	  
of included genetic polymorphisms as well as a casual impaired factors distribution between the 222	  
study arms, the potential need for therapeutic drug monitoring even in the PG-based arm. 223	  
Once in a lifetime performed genetic testing offers the possibility to know in advance the likelihood 224	  
of an individual patient to achieve a more appropriate atazanavir pharmacokinetic exposure and to 225	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choose the frequency of administration accordingly; if confirmed, this observation supports the use 226	  
of pharmacogenetics for treatment tailoring in atazanavir-receiving HIV-positive patients. 227	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Tables 347	  
Characteristic 
Standard dose 
arm 
(n= 40) 
Pharmacogenetic 
arm 
(n= 40) 
p 
values 
Age (years): median (IQR) 43 (37-47) 44 (38-50) 0.424 
Male gender: n (%) 28 (70%) 30 (75%) 0.783 
Ethnicity: n (%) 
White 
Black 
Other 
 
37 (92.5%) 
1 (2.5%) 
2 (5%) 
 
34 (85%) 
3 (7.5%) 
3 (7.5%) 
0.487 
BMI (Kg/m2): median (IQR) 22.9 (20.2-25.3) 23.9 (21-26.2) 0.421 
Duration of HIV infection (years): median (IQR) 5.9 (3.7-12.4) 7.3 (3.7-12.3) 0.665 
CD4+ T lymphocytes (cells/mm3): median (IQR) 541 (428-628) 467 (320-600) 0.063 
CD4+/CD8+ T lymphocytes ratio: median (IQR) 0.65 (0.53-1.1) 0.60 (0.5-1.29) 0.864 
Hepatitis B surface antigen positive: n (%) 6 (15%) 1 (2.5%) 0.049 
Hepatitis C antibody positive: n (%) 8 (20%) 8 (20%) 0.823 
Single nucleotide polymorphisms: n (%) 
PXR 63396 TT 
ABCB1 3435 CT/TT 
SLCO1B1 521 TT 
 
 
12 (30%) 
28 (70%) 
30 (75%) 
 
 
10 (25%) 
29 (72.5%) 
33 (82.5%) 
 
 
0.848 
0.364 
0.848 
Favorable pharmacogenotypic score (<=1): n (%) 14 (35%) 13 (32.5%) 0.797 
	  348	  
Table 1. Demographics, immunovirological and pharmacogenetic characteristics of 349	  
randomized patients. Values were compared between the two arms using Chi-square (Fisher’s 350	  
exact test where appropriate) for categorical values and Mann-Whitney test for continuous variable; 351	  
two-sided p values are shown in the last column. “IQR”: interquartile range.  352	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 359	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 377	  
Figure 1. Atazanavir average concentration (weeks 4 to 12) according to study arm. Symbols 378	  
indicate geometric mean of trough concentration obtained at weeks 4, 8 and 12; the horizontal lines 379	  
represent median values. The gray boxes represent the percentage of patients with average exposure 380	  
above 150 ng/mL. 381	  
 382	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Figure 3. Atazanavir average concentration (weeks 4 to 12) according to study arm. Symbols indicate 
geometric mean of trough concentration obtained at weeks 4, 8 and 12; the horizontal lines represent median 
values. The gray box s represent the percentage of patients with average exposure above 150 ng/mL. 
